Please login to the form below

Not currently logged in
Email:
Password:

Combined hypertension drug recommended

A study published in The Lancet has recommended a combination of two drugs for the treatment of high blood pressure

A study published in The Lancet has recommended a combination of two drugs for the treatment of high blood pressure.

The research, funded by Novartis, investigated a combination of the renin inhibitor aliskiren and the calcium channel blocker amlodipine in the early control of high blood pressure in comparison with each drug used on its own.

Aliskiren is marketed by Novartis as Tekturna in the US, and as Rasilez elsewhere. Amlodipine was developed and commercialised as Norvasc by Pfizer, although its patent expired in 2007. The combination drug, which was approved by the US Food and Drug Administration (FDA) in 2010, is marketed by Novartis as Tekamlo.

Over 1,200 participants with essential hypertension – defined as high blood pressure with no identifiable cause – were involved in the study, with trials spread over ten countries.

Initially, around half of the people involved in the trial were given the combination therapy, while the remaining participants was split into two further groups each taking an individual therapy plus placebo. All individuals were then switched to the combination therapy at 16 weeks.

Results showed that patients originally given the combination treatment had a 6.5mm Hg increased reduction in mean systolic blood pressure - the maximum pressure exerted when the heart contracts, pushing blood into the arteries.

Associate medical director for the British Heart Foundation, Professor Jeremy Pearson, commented on the results: "This study adds significantly to the evidence that starting treatment for patients with high blood pressure with two medicines rather than one is safe, and more effective than waiting to add the second medicine later.

"Good control of blood pressure is still hard to achieve in many patients. So we are currently funding follow-up trials to this research that will find out the best way to treat patients whose hypertension is still poorly controlled with two drugs, and who need extra medicines."

The Lancet has the study available to subscribers.

13th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics